What is Zealand Pharma's post-Lyxumia future?
This article was originally published in Scrip
Executive Summary
Zealand Pharma, with its partner Sanofi, is expecting a positive recommendation from the European Medicines Agency's CHMP for its type 2 diabetes treatment lixisenatide at any moment. The GLP-1 agonist is shaping up to be the only serious competitor to Novo Nordisk's hugely successful GLP-1 agonist Victoza (liraglutide).